Merck & Co., Inc. Halts Blood Thinner Study in Stroke Patients, Limiting Possible Sales

Bloomberg -- A study of Merck & Co.’s vorapaxar, an anticlotting pill that had potential for $5 billion in annual sales, was halted and a second trial narrowed in scope, limiting the drug’s possible use.